# A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

> **NCT02989584** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 54 (actual)

## Conditions studied

- Bladder Cancer
- Metastatic Bladder Cancer
- Urothelial Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02989584
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-12-20
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02989584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02989584, "A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02989584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*